FCA
SWTX

FinTrust Capital Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

FinTrust Capital Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$641 Hold
20
– – ﹤0.01% 1307
2024
Q2 		$754 Hold
20
– – ﹤0.01% 1282
2024
Q1 		$985 Hold
20
– – ﹤0.01% 1170
2023
Q4 		$730 Hold
20
– – ﹤0.01% 1174
2023
Q3 		$463 Buy
+20
New +$547 ﹤0.01% 1169

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

FinTrust Capital Advisors's SWTX Position: Q3 2024 in Review

FinTrust Capital Advisors held its SpringWorks Therapeutics (SWTX) position steady in Q3 2024 at 20 shares worth $641. The position accounts for ﹤0.01% of the portfolio, ranked #1307.

FinTrust Capital Advisors first reported a position in SWTX in Q3 2023 and has held it in 5 quarters since. The position peaked at $985 in Q1 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • FinTrust Capital Advisors held 20 shares of SpringWorks Therapeutics worth $641 as of Q3 2024.
  • FinTrust Capital Advisors left its SpringWorks Therapeutics share count unchanged in Q3 2024.
  • SpringWorks Therapeutics made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1307 holding.
  • FinTrust Capital Advisors first reported a position in SpringWorks Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • FinTrust Capital Advisors's SpringWorks Therapeutics position peaked at $985 in Q1 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.